Developing Next Generation Psychedelic Medicines to Treat Mental Illness
Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, rapid-acting medicines to treat neurological and psychiatric disorders, such as treatment-resistant depression, post-traumatic stress disorder (PTSD), and alcohol misuse.
About us
The company has identified and patented a new class of proprietary ligands. The lead compound LPH-5 is a highly selective small-molecule agonist of the Serotonin HT2AR and exhibits robust CNS exposure, target engagement and efficacy in animal models of depression. LPH-5 successfully completed IND enabling GLP Tox studies in Q4 2022 and is now advancing to Phase I.
After being spun out from University of Copenhagen and the first investment from the Novo Nordisk Foundation, the company has received funding from Innovation Fund Denmark and a syndicate of family offices and private individuals.
Lophora Founders Team at BioInnovation Institute (October 2020). From left: Emil Märcher-Rørsted, Jesper Langgaard Kristensen, Bo Tandrup, Anders Asbjørn Jensen.
